[go: up one dir, main page]

CU20190104A7 - Formulación estable del anticuerpo nimotuzumab - Google Patents

Formulación estable del anticuerpo nimotuzumab

Info

Publication number
CU20190104A7
CU20190104A7 CU2019000104A CU20190104A CU20190104A7 CU 20190104 A7 CU20190104 A7 CU 20190104A7 CU 2019000104 A CU2019000104 A CU 2019000104A CU 20190104 A CU20190104 A CU 20190104A CU 20190104 A7 CU20190104 A7 CU 20190104A7
Authority
CU
Cuba
Prior art keywords
stable formulation
nimotuzumab
antibody
nimotuzumab antibody
stable
Prior art date
Application number
CU2019000104A
Other languages
English (en)
Inventor
Ayo Tammy Boggiano
Vitloch Adolfo Castillo
Arias Mercedes Cedeño
Sáez Olga Lidea Fernández
Terrero Yaiko Saddan Hernández
Monzón Kalet León
De La Luz Hernández Kathya Rashida
Tomás Pompa Julio Felipe Santo
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2019000104A priority Critical patent/CU20190104A7/es
Priority to US17/786,094 priority patent/US20230018364A1/en
Priority to BR112022010488A priority patent/BR112022010488A2/pt
Priority to CA3163630A priority patent/CA3163630A1/en
Priority to MX2022007509A priority patent/MX2022007509A/es
Priority to KR1020227024674A priority patent/KR20220119091A/ko
Priority to CN202080088100.8A priority patent/CN114867468A/zh
Priority to JP2022536924A priority patent/JP7796646B2/ja
Priority to EP20903282.0A priority patent/EP4079294A2/en
Priority to PCT/CU2020/050007 priority patent/WO2021121444A2/es
Priority to AU2020409887A priority patent/AU2020409887B2/en
Publication of CU20190104A7 publication Critical patent/CU20190104A7/es
Priority to CONC2022/0009693A priority patent/CO2022009693A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La presente invención se relaciona con las ramas de Ia Biotecnología y Ia Medicina y describe formulaciones farmacéuticas de alta concentración que comprenden al anticuerpo monoclonal humanizado nimotuzumab en un rango de concentración entre 50 a 200 mg/mL. Los bajos valores de viscosidad de dichas soluciones permiten su empleo por vía subcutánea o intramuscular en el tratamiento del cáncer. Estas formulaciones son estables tanto en sus formas líquidas como liofilizadas.<br /> </p>
CU2019000104A 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab CU20190104A7 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU2019000104A CU20190104A7 (es) 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab
KR1020227024674A KR20220119091A (ko) 2019-12-17 2020-12-10 항체 니모투주맙(nimotuzumab)의 안정한 고농축 제형
BR112022010488A BR112022010488A2 (pt) 2019-12-17 2020-12-10 Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente
CA3163630A CA3163630A1 (en) 2019-12-17 2020-12-10 Stable and highly concentrated formulation of the antibody nimotuzumab
MX2022007509A MX2022007509A (es) 2019-12-17 2020-12-10 Formulacion estable y de alta concentracion del anticuerpo nimotuzumab.
US17/786,094 US20230018364A1 (en) 2019-12-17 2020-12-10 Stable high-concentration forumulation of nimotuzumab antibody
CN202080088100.8A CN114867468A (zh) 2019-12-17 2020-12-10 尼妥珠单抗的稳定和高浓度制剂
JP2022536924A JP7796646B2 (ja) 2019-12-17 2020-12-10 抗体ニモツズマブの安定で高濃度の製剤
EP20903282.0A EP4079294A2 (en) 2019-12-17 2020-12-10 Stable and highly concentrated formulation of the antibody nimotuzumab
PCT/CU2020/050007 WO2021121444A2 (es) 2019-12-17 2020-12-10 Formulación estable y de alta concentración del anticuerpo nimotuzumab
AU2020409887A AU2020409887B2 (en) 2019-12-17 2020-12-10 Stable and highly concentrated formulation of the antibody nimotuzumab
CONC2022/0009693A CO2022009693A2 (es) 2019-12-17 2022-07-11 Formulación estable y de alta concentración del anticuerpo nimotuzumab

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2019000104A CU20190104A7 (es) 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab

Publications (1)

Publication Number Publication Date
CU20190104A7 true CU20190104A7 (es) 2021-08-06

Family

ID=76478863

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000104A CU20190104A7 (es) 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab

Country Status (12)

Country Link
US (1) US20230018364A1 (es)
EP (1) EP4079294A2 (es)
JP (1) JP7796646B2 (es)
KR (1) KR20220119091A (es)
CN (1) CN114867468A (es)
AU (1) AU2020409887B2 (es)
BR (1) BR112022010488A2 (es)
CA (1) CA3163630A1 (es)
CO (1) CO2022009693A2 (es)
CU (1) CU20190104A7 (es)
MX (1) MX2022007509A (es)
WO (1) WO2021121444A2 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2007260769A1 (en) * 2006-06-14 2007-12-21 Imclone Llc Lyophilized formulations of anti-EGFR antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
PE20150964A1 (es) * 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
EP3541413A2 (en) * 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN107898756B (zh) * 2017-12-22 2020-11-20 东曜药业有限公司 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用

Also Published As

Publication number Publication date
EP4079294A2 (en) 2022-10-26
US20230018364A1 (en) 2023-01-19
CA3163630A1 (en) 2021-06-24
CO2022009693A2 (es) 2022-07-19
CN114867468A (zh) 2022-08-05
MX2022007509A (es) 2022-07-01
BR112022010488A2 (pt) 2022-09-06
AU2020409887A1 (en) 2022-08-11
WO2021121444A2 (es) 2021-06-24
JP2023509354A (ja) 2023-03-08
JP7796646B2 (ja) 2026-01-09
KR20220119091A (ko) 2022-08-26
WO2021121444A3 (es) 2022-02-24
AU2020409887B2 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
MA47313A (fr) Formulations sous-cutanées d&#39;anticorps her2
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
AR107708A1 (es) Formulaciones de antagonista de il-6 y sus usos
CL2016003335A1 (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
AR110424A1 (es) Moléculas de unión a adam9 y métodos de uso de las mismas
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
CU20190104A7 (es) Formulación estable del anticuerpo nimotuzumab
CL2024003444A1 (es) Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano.
DOP2025000008A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
MX2021012869A (es) Anticuerpo anti-tie2 y uso del mismo.
MX2021002500A (es) Anticuerpos y secuencias de nucleotidos novedosos, y sus usos.
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
AR119973A1 (es) Composiciones y métodos de anticuerpos anti-cd39
CO2025017899A2 (es) Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco
AR129553A1 (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo